Key result
Pregnancy in CVD requires CARPREG or WHO risk assessment and multidisciplinary care to mitigate risks.
Pregnancy in women with heart disease requires careful risk assessment and multidisciplinary management, including specific anticoagulation strategies such as switching warfarin to heparin.
Answers are grounded in this paper and cite their sources.
Supports multidisciplinary management using CARPREG/WHO in pregnant women with CVD; leaves open prospective validation of risk tools.
Heart disease is a major cause of mortality and morbidity in pregnant women.It is reported in 0.2 to 4% of all pregnancies.The incidence of heart disease in pregnancy has increased in the last two decades due to better surgical treatment for congenital heart disease, due to which more number of women are surviving to reach adulthood and opting to conceive and continue pregnancy.Pregnancy is associated with major physiological adaptations in to ensure adequate blood supply to uterus and to ensure blood supply to growing fetus.The net result is increase in cardiac output, plasma volume, heart rate and decrease in systemic vascular resistance.Risk assessment in pregnancy is based on CARPREG scoring system.Patient should be informed about the increased chance of miscarriage, prematurity and fetal growth restriction.If pregnant female is on warfarin it needs to be switched to heparin at pregnancy detection and again at 36 weeks.In general, vaginal delivery is preferred and delivery should occur in tertiary centres with readily available team of cardiologist, anesthetist, senior obstetrician and neonatologist.
No takes yet. Share an insight, caveat, or question.
Yadav et al. (2019) conducted a review in Cardiovascular disease in pregnancy. Pregnancy in women with cardiovascular disease requires careful risk assessment using CARPREG or WHO classifications and multidisciplinary management to mitigate maternal and fetal risks.
Synapse has enriched 10 related papers. Consider them for comparative context: